BioStem Technologies (BSEM) vs Dogwood Therapeutics (DWTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioStem Technologies (BSEM) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 45.0% versus a loss of 77.9%. Over five years, BSEM leads with a +88.6% price change compared with -98.8% for DWTX. Dogwood Therapeutics is the larger company by market cap ($48.9 million vs $47.2 million), about 1.0 times the size.
On valuation, Dogwood Therapeutics trades at a lower trailing P/E (0.7x vs 2.9x for BioStem Technologies).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | DWTX |
|---|---|---|
| Share price | $2.53 | $1.44 |
| Market cap | $47.24M | $48.95M |
| 1-day change | -4.17% | +2.13% |
| YTD return | -30.71% | -66.11% |
| 1-year return | -45.00% | -77.90% |
| 5-year return | +88.57% | -98.80% |
| P/E ratio (TTM) | 2.88 | 0.65 |
| Forward P/E | 8.72 | — |
| EPS (TTM) | $0.88 | $2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $7.04 |
| 52-week low | $2.25 | $1.28 |
| Distance from 52-week high | -69.88% | -79.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +176.68% | +872.22% |
| Average volume | 124.14K | 63.50K |
| Shares outstanding | 18.67M | 33.99M |
| Employees | 73 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BSEM has outperformed DWTX by 32.9 percentage points over the past year.
- BioStem Technologies trades at a higher earnings multiple (2.9x vs 0.7x trailing P/E).
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
BSEM vs DWTX FAQ
Which is bigger, BioStem Technologies or Dogwood Therapeutics?
Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $48.95M compared with $47.24M for BioStem Technologies (BSEM).
Which stock has performed better over the past year, BSEM or DWTX?
BSEM returned -45.00% over the past 12 months, compared with -77.90% for DWTX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BSEM or DWTX?
DWTX has the lower trailing P/E at 0.7, versus 2.9 for BSEM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BioStem Technologies and Dogwood Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioStem Technologies and Biotechnology: Pharmaceutical Preparations for Dogwood Therapeutics.